Dosage should be adjusted according to each patient’s needs. It is recommended that nifedipine extended-release tablets be administered orally once daily on an empty stomach. Nifedipine extended-release tablet is an extended release dosage form and tablets should be swallowed whole, not bitten or divided. In general, titration should proceed over a 7 to14 day period starting with 30 mg once daily. Upward titration should be based on therapeutic efficacy and safety. The usual maintenance dose is 30 mg to 60 mg once daily. Titration to doses above 90 mg daily is not recommended.
If discontinuation of nifedipine extended-release tablets is necessary, sound clinical practice suggests that the dosage should be decreased gradually with close physician supervision.
Care should be taken when dispensing nifedipine extended-release tablets to assure that the extended-release dosage form has been prescribed.
NDC:64725-2057-1 in a BOTTLE of 100 TABLET, EXTENDED RELEASES
The tablets should be protected from light and moisture and stored at 25ºC (77ºF); excursions permitted to 15-30ºC (59-86ºF) [see USP Controlled Room Temperature]. Dispense in tight, light-resistant containers.
Manufactured in Canada by: Valeant Pharmaceuticals International, Inc. Steinbach, MB R5G1Z7 Canada
Manufactured for: TEVA PHARMACEUTICALS USA Sellersville, PA 18960
| NIFEDIPINE |
nifedipine tablet, extended release
|Labeler — TYA Pharmaceuticals (938389038)|
|Registrant — TYA Pharmaceuticals (938389038)|
|TYA Pharmaceuticals||938389038||RELABEL (64725-2057), REPACK (64725-2057)|
Revised: 08/2013 TYA Pharmaceuticals
All MedLibrary.org resources are included in as near-original form as possible, meaning that the information from the original provider has been rendered here with only typographical or stylistic modifications and not with any substantive alterations of content, meaning or intent.